01

CXCL10 Identified as Response Biomarker for Ruxolitinib Cream in Vitiligo

CXCL10 correlates with clinical response to ruxolitinib cream in vitiligo, per the Phase 2 TRuE-V mechanism-of-action study published October 13, 2026, in JID.